Division of Emergent BioSolutions Inc.
Latest From Cangene Corp.
The pace of pharma dealmaking continued unabated in 2015, climaxing with Pfizer’s agreed $160 billion merger with Allergan. Conditions are right for this situation to persist, at least for the foreseeable future.
Twelve novel biologics in 2015 sets record, with 'biobetter' coagulation factors again making up largest group of new products.
The latest drug development news and highlights from our FDA Performance Tracker.
Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced December 2013 through January 2014.
- Specialty Pharmaceuticals
- Therapeutic Areas
- Immune Disorders
- Infectious & Viral Diseases
- North America
- Parent & Subsidiaries
- Emergent BioSolutions Inc.
- Senior Management
John A Sedor, Pres. & CEO
Jeff Lamothe, CFO
Laura Saward, PhD, CSO
Chris Sinclair, VP, Bus. Dev. & Corp. Strategic Planning
Michael Adelman, VP, Commercial Operations
- Contact Info
Phone: (204) 275-4200
155 Innovation Dr.
Winnipeg, R3T 5Y3
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.